United States, Nevada, Las Vegas, DelveInsight’s ‘Diabetic Foot Ulcer Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.
Key Takeaways from the Diabetic Foot Ulcer Pipeline Report
- Over 34+ Diabetic Foot Ulcer pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Foot Ulcer market would significantly increase market revenue.
- Leading Diabetic Foot Ulcer companies developing novel drug candidates to improve the Diabetic Foot Ulcer treatment landscape include Aurealis Therapeutics, Charsire Biotechnology Corporation, and others.
- Promising Diabetic Foot Ulcer pipeline therapies in various stages of development include AUP 16, CSTC 1, and others.
Diabetic Foot Ulcer Overview
A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.
Diabetic Foot Ulcer Pipeline Analysis: Drug Profile
AUP 16: Aurealis Therapeutics
AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.
Discover more about the emerging Diabetic Foot Ulcer drugs @ Diabetic Foot Ulcer Treatment Drugs
Diabetic Foot Ulcer Key Companies
- Aurealis Therapeutics
- Charsire Biotechnology Corporation
Diabetic Foot Ulcer Pipeline Therapies
- AUP 16
- CSTC 1
Diabetic Foot Ulcer Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Diabetic Foot Ulcer Pipeline Report
- Coverage: Global
- Key Diabetic Foot Ulcer Companies: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others
- Key Diabetic Foot Ulcer Pipeline Therapies: AUP 16, CSTC 1, and others
Find out more about the Diabetic Foot Ulcer treatment options in development @ Diabetic Foot Ulcer Clinical Trials
Table of Contents
2. Executive Summary
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
16. About DelveInsight
Request for a sample report to know more about the leading companies in the Diabetic Foot Ulcer pipeline domain.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States